XML 31 R13.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Intangible Assets, Net | 12 Months Ended
--- | ---
Dec. 31, 2023
Intangible Assets, Net |
Intangible Assets, Net | 7. Intangible Assets, Net As of December 31, 2023, the Company’s definite-lived intangible assets, which totaled $7,028, resulted from the capitalization of certain milestone payments made to Ipsen Pharma, S.A.S., or Ipsen, in accordance with the terms of the Company’s license agreement with Ipsen, in connection with the Company’s first commercial sale of IMCIVREE in the U.S. in March 2021. As of December 31, 2023, amortization expense for the next five years and beyond is summarized as follows: ​ ​ ​
​ | ​ | ​ | ​
2024 | ​ | $ | 855
2025 | ​ | ​ | 855
2026 | ​ | ​ | 855
2027 | ​ | ​ | 855
2028 | ​ | ​ | 855
Thereafter | ​ |  | 2,753
Total | ​ | $ | 7,028
​ The Company began amortizing its finite-lived intangible assets in April 2021 over an 11 year period based on IMCIVREE’s expected patent exclusivity period. Amortization expense totaled $855, $774 and $342 for the years ended December 31, 2023, 2022 and 2021, respectively. Amortization expense is recorded as a component of cost of sales on the consolidated statements of operations and comprehensive loss.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration